⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
GLP-1 Receptor Agonists
Current understanding
Semaglutide-class drugs; mortality and inflammation signals are pulling them into the longevity conversation.
Evidence log
- 2026-11-12 — Could microdosing GLP-1 drugs boost longevity?: [anecdotal-biohack] Scientific American news report, no new primary data, describes GLP-1 microdosing as an emerging biohacking and off-label clinical practice aimed at longevity with fewer gastrointestinal effects and less unwanted weight loss; enthusiasm outruns the evidence, as the report does not establish these benefits or show that microdosing retains benefits demonstrated at trial-tested doses. [anecdotal-biohack] (novelty: 3)
- 2026-11-13 — Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.: [human-observational] Systematic review and meta-analysis of 30 studies (>5,600 participants; DXA/BIA assessments) reported greater total weight and absolute fat- and lean-mass loss after metabolic/bariatric surgery than GLP-1-based therapy at 12 months, without clearly demonstrating poorer proportional lean-mass preservation after surgery; this comparison is conservatively classified because randomized head-to-head evidence is not specified, and it does not establish equivalent preservation or functional safety. [human-observational] (novelty: 3)
- 2026-11-09 — Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes: [expert-opinion] Early clinical-trial description, no results reported: a 24-week study in adults with type 2 diabetes initiating semaglutide or tirzepatide is evaluating supervised resistance/interval training plus daily whey protein for preservation of thigh muscle volume, strength, and physical function; this does not establish preventive efficacy or overturn existing findings of preserved function despite muscle-volume loss. [expert-opinion] (novelty: 3)
- 2026-11-11 — Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.: [human-rct] COURAGE, a two-part phase 2 double-blind placebo-controlled RCT (n=975) in adults with obesity receiving semaglutide, found trevogrumab significantly attenuated lean-mass loss with reported good tolerability, whereas adding garetosmab further improved body composition but produced unacceptable adverse events; lean-mass preservation does not itself establish functional benefit or negate the logged STEP UP finding of preserved sit-to-stand function despite muscle-volume loss. [human-rct] (novelty: 4)
- 2026-11-12 — Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?: [expert-opinion] The authors of “Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?” propose muscle-preserving drug adjuncts as potentially essential for durable metabolic and functional benefits, but this review adds no new primary outcome data establishing their necessity or efficacy; this framing remains in tension with the logged [human-rct] STEP UP secondary analysis showing preserved sit-to-stand function despite modest muscle-volume loss. [expert-opinion] (novelty: 3)
- 2026-11-10 — Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.: [expert-opinion] The authors of “Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy” flag appetite-related nutritional shortfalls during incretin therapy as potentially compounding menopausal muscle and bone vulnerability and propose protein optimization and targeted clinical care; this review supplies no new primary data establishing accelerated sarcopenic obesity or osteoporosis or preventive efficacy, and its risk framing contrasts with the logged STEP UP finding of preserved sit-to-stand function and meta-analysis showing no significant bone-density or fracture effects without resolving menopause-specific risks. [expert-opinion] (novelty: 3)
- 2026-03-31 — Reprogramming the mitochondrial-circadian energy code with incretins.: [mechanism-plausible] Review, no new primary data: biology suggests GLP-1 and dual GLP-1/GIP agonists could influence aging through mitochondrial efficiency and circadian alignment, but no outcome study presented confirms the proposed systemic geroprotection or added longevity benefit from combining incretins with senolytics, NAD+ support, and chrono-entrainment. [mechanism-plausible] (novelty: 3)
- 2026-10-01 — Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.: [human-observational] Clinical cohort of patients undergoing intensive cardiac rehabilitation found no statistically significant excess skeletal muscle mass loss in GLP-1 receptor agonist users versus non-users, qualifying concerns about muscle loss in this setting without establishing equivalence, proving that rehabilitation prevents muscle loss, or resolving strength and functional safety questions. [human-observational] (novelty: 3)
- 2026-10-22 — Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.: [human-observational] Real-world observational study (n=13,387) in adults aged ≥65 with obesity and without diabetes found sustained versus minimal GLP-1 receptor agonist exposure associated with greater BMI and HbA1c reductions and approximately half the incidence of diabetes; residual confounding limits causal interpretation, and these outcomes do not establish lifespan extension or resolve muscle and functional safety questions. [human-observational] (novelty: 3)
- 2026-10-26 — Identification of TAS2R-targeting bioactive compounds against metabolic decline: A novel ex vivo methodology based on enteroendocrine and inflammatory readouts.: cross-connection with resveratrol: [mechanism-plausible] Biology suggests a connection through endogenous GLP-1 secretion following intestinal TAS2R stimulation, but this is distinct from direct GLP-1 receptor agonism; no outcome study in this finding confirms comparable metabolic effects. (novelty: 3)
- 2026-10-27 — Cardiovascular Effects of GLP-1 Receptor Agonists Across Age Groups: An Updated Meta-Analysis of Randomized Controlled Trials.: [human-rct] Updated meta-analysis of eight cardiovascular outcome RCTs (n=71,926, including SELECT and SOUL) found GLP-1 receptor agonists reduced major adverse cardiovascular events with comparable relative risk reductions in adults aged ≥65 and younger participants and no statistically significant age-dependent attenuation; this synthesis does not establish identical absolute benefits, resolve muscle or nutritional safety concerns, or demonstrate general lifespan extension. [human-rct] (novelty: 3)
- 2026-11-04 — GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.: [mechanism-plausible] In vitro study in primary human myotubes found direct semaglutide or GIP exposure did not induce atrophy-related gene expression or impair myogenesis under tested conditions, arguing against direct muscle toxicity in this model without proving caloric restriction or unloading causes clinical lean-mass loss or establishing muscle preservation in patients. [mechanism-plausible] (novelty: 3)
- 2026-11-05 — Obesity pharmacotherapies and cognition.: [expert-opinion] The authors of “Obesity pharmacotherapies and cognition” synthesize mixed clinical, observational, and preclinical findings, identifying receptor pharmacology, CNS exposure, and baseline metabolic status as potential determinants of cognitive effects; this review adds no new primary data and qualifies rather than confirms the previously logged observational cognitive-benefit signal. [expert-opinion] (novelty: 3)
- 2026-11-08 — Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP-1 Weight Loss.: [expert-opinion] The authors of “Weaker or Just Lighter?” propose ‘functional discordance’ between lean-mass changes and physical function and a grip-strength, chair-stand, and gait-speed monitoring protocol for older or high-risk adults receiving GLP-1 therapy; this review adds no primary data validating the protocol or demonstrating functional decline and does not overturn the logged STEP UP RCT finding of preserved sit-to-stand function. [expert-opinion] (novelty: 3)
- 2026-10-26 — Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.: [expert-opinion] Review synthesizing trial and observational evidence interprets incretin-associated lean-mass reductions as proportional to weight loss without consistent strength or performance impairment, qualifying rather than resolving existing sarcopenia concerns and proposing functional monitoring and lifestyle countermeasures for vulnerable older adults; no new primary data establish safety or preventive efficacy in these populations. [expert-opinion] (novelty: 3)
- 2026-10-29 — Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.: [expert-opinion] The authors of this geriatric prescribing review apply the Geriatrics 5Ms framework to incretin-based obesity treatment and frame resistance training and adequate protein as essential co-interventions to address potential lean-mass loss and functional decline in older adults; no new primary data establish these preventive effects, and the risk framing contrasts with existing SELECT frailty and STEP UP functional findings rather than overturning them. [expert-opinion] (novelty: 3)
- 2026-10-01 — Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.: [human-observational] Multicenter TriNetX propensity-matched cohort analysis drawing on over 380,000 adults with obesity found dual GIP/GLP-1 agonist tirzepatide use associated with reported relative reductions of 47% in new-onset heart failure and 69% in one-year all-cause mortality, alongside lower MACE; residual confounding limits causal interpretation, and these associations do not establish heart-failure prevention or general longevity benefits. [human-observational] (novelty: 3)
- 2026-08-25 — Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m: A Target Trial Emulation.: [human-observational] Target trial emulation in adults with type 2 diabetes and BMI <27 kg/m² found GLP-1 receptor agonist use associated with lower heart failure risk versus DPP-4 inhibitors, SGLT2 inhibitors, and usual care; residual confounding limits causal interpretation, and this finding does not establish weight-loss-independent effects or general longevity benefits. [human-observational] (novelty: 3)
- 2026-11-01 — Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.: [human-observational] Active-comparator target trial emulation involving over 1.5 million matched adults with serious mental illness found GLP-1 receptor agonist initiation associated with significantly lower all-cause mortality and major adverse cardiovascular event rates than SGLT2 inhibitor initiation; residual confounding limits causal interpretation, and this does not establish general longevity benefits. [human-observational] (novelty: 3)
- 2026-10-16 — GLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational study.: [human-observational] Nationwide observational study of patients undergoing aortic valve replacement for severe aortic stenosis found GLP-1 receptor agonist treatment associated with significantly lower all-cause mortality, heart failure hospitalization, and valve reoperation; residual confounding limits causal interpretation, and these associations do not establish valve protection or general longevity benefits. [human-observational] (novelty: 3)
- 2026-10-09 — Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.: [human-observational] Retrospective cohort of patients with type 2 diabetes and COPD found dual GIP/GLP-1 agonist tirzepatide associated with lower all-cause mortality versus SGLT2 inhibitors, DPP-4 inhibitors, and other GLP-1 receptor agonists, and fewer COPD exacerbations versus SGLT2 and DPP-4 inhibitors; residual confounding limits causal interpretation, and an exacerbation advantage over other GLP-1 agonists is not established by the supplied finding. [human-observational] (novelty: 3)
- 2026-10-28 — Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.: [human-observational] Propensity-matched MASLD cohort found higher mortality, cardiovascular events, and cancer in normal-BMI versus obese patients, alongside less frequent incretin prescribing and an association between incretin use and better survival; residual confounding prevents causal interpretation, and lower prescribing alone does not establish undertreatment or BMI-based access restrictions as its cause. [human-observational] (novelty: 3)
- 2026-10-29 — GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.: [human-observational] Propensity-score-matched cohort of over 27,000 patients with abdominal aortic aneurysm found GLP-1 receptor agonist use associated with reported relative reductions of 46% in aneurysm rupture and 53% in five-year all-cause mortality; residual confounding limits causal interpretation, and these findings do not establish aneurysm protection or general longevity benefits. [human-observational] (novelty: 3)
- 2026-10-30 — Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.: [human-observational] Population-based, propensity-matched active-comparator cohort in patients with COPD and type 2 diabetes found GLP-1 receptor agonist use associated with lower risks of sepsis, pneumonia, and all-cause mortality (mortality HR 0.656) versus DPP-4 inhibitors; residual confounding limits causal interpretation, and these findings do not establish longevity benefits outside this population. [human-observational] (novelty: 3)
- 2026-10-10 — “Ozempic Face” and Facial Aging.: Clinical review on ‘Ozempic face’ synthesizes anatomy (fat-pad deflation, skin laxity, loss of structural support) and dermatologic management strategies for rapid GLP-1-induced weight loss — practice-framing synthesis, no new causal data beyond existing recognition of the phenomenon. [expert-opinion] (novelty: 3)
- 2026-09-29 — Vibegron for ENergy Thinking and Resilience in Aging: cross-connection with vibegron: Both target midlife/older adults with obesity for cardiometabolic and functional endpoints; vibegron tests a sympathomimetic/thermogenic mechanism as an alternative to appetite-suppression pathways. (novelty: 3)
- 2026-07-30 — Complementary body weight and cardiometabolic benefits of higher GLP-1 and lower GIP: genetic evidence from large-scale phenomic analyses.: UK Biobank TreeWAS plus factorial Mendelian randomization found genetically predicted higher physiological GLP-1 combined with lower GIP associated with complementary reductions in obesity, CVD, VTE, and hepatic events — with body weight a plausible mediator and no bone-metabolism harm signal — supporting a complementary GLP-1-up/GIP-down pharmacological direction without a trial readout. [human-observational] (novelty: 3)
- 2026-07-23 — Glucagon-like Peptide-1 Receptor Agonist Use May Reduce Disease Activity and Progression in Osteoarthritis and Inflammatory Arthritis.: Narrative review proposes GLP-1 RAs may reduce disease activity and progression in osteoarthritis and inflammatory arthritis through anti-inflammatory, analgesic, and chondroprotective mechanisms beyond weight loss, synthesizing preclinical, RCT, and mixed observational signals — review-level synthesis, no new primary data and contradicts the parallel OA-pharmacotherapy review that found no structural joint modification. [expert-opinion] (novelty: 3)
- 2026-10-05 — Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.: Narrative review on GIPR pharmacology notes GLP-1R agonism can be augmented by either GIPR agonism (tirzepatide) or GIPR antagonism (maridebart cafraglutide), with the two combination strategies producing larger weight loss than GLP-1R alone via divergent central mechanisms; synthesis of existing trial and preclinical data, no new primary evidence on GLP-1 agents themselves. [expert-opinion] (novelty: 3)
- 2026-10-07 — Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy.: Clinical-mechanistic review distinguishes GLP-1-associated lean-mass reduction (largely non-contractile, often with preserved/improved muscle quality) from true skeletal muscle loss, and recommends judging therapy success by fat loss plus preserved muscle mass and function supported by protein intake, resistance training, and functional monitoring — synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-06 — A Systematic Review and Meta-Analysis of Malnutrition and Metabolic Failure in High-Potency Incretin Therapy.: Meta-analysis of 19 RCTs on high-potency incretin therapies quantifies large energy deficits and under-recognized malnutrition plus measurable fat-free-mass loss that standard adverse-event reporting misses, and proposes a structured nutritional monitoring algorithm to prevent sarcopenia/frailty especially in adults ≥65. [human-rct] (novelty: 3)
- 2026-09-27 — Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.: Preclinical cell study positions fisetin as an ACVR2A inhibitor that protects myotubes from Activin A-induced atrophy, flagging it as a candidate adjunct for the GLP-1-associated lean-mass loss problem — mechanism-level only, no animal or human combination data. [mechanism-plausible] (novelty: 3)
- 2026-09-29 — Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.: Narrative review on aesthetic surgery reframes GLP-1-associated lean soft-tissue loss (~25–30% of total weight lost) as pharmacologically distinct from age-related sarcopenia and potentially relevant to surgical tissue quality (skin laxity, flap/wound integrity), but direct surgical-outcome evidence is limited to case reports and one small cohort. [expert-opinion] (novelty: 3)
- 2026-10-02 — Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.: Polish Society of Dietetics scientific statement recommends structured dietitian-led care during GLP-1 and dual GIP/GLP-1 obesity therapy — adequate protein, resistance exercise, Mediterranean/DASH or planned plant-based patterns, and targeted (not routine) micronutrient supplementation — to limit lean-mass loss and nutrient shortfalls; society guidance document, no new primary data. [expert-opinion] (novelty: 3)
- 2026-10-02 — Semaglutide Demonstrates Benefits Across Frailty Levels.: News-report restates headline that semaglutide benefits hold across frailty strata, echoing the earlier SELECT post-hoc frailty analysis — media coverage, no new primary data beyond the already-logged RCT secondary analysis. [expert-opinion] (novelty: 3)
- 2026-06-17 — Age-related macular degeneration associated with glucagon-like peptide-1 receptor agonist use: a systematic review.: Systematic review of observational cohorts on GLP-1 RA ocular safety found a signal toward lower nonexudative AMD incidence and mixed neutral-or-protective findings for neovascular AMD, graded very low certainty — qualitative synthesis, no RCT evidence on AMD endpoints. [human-observational] (novelty: 3)
- 2026-07-18 — GLP1 Mimetics and Stem Cells: An Intersection of Metabolic and Regenerative Medicine.: Editorial frames an emerging intersection between GLP-1 receptor agonists and stem-cell/regenerative biology, suggesting GLP-1RAs may modulate embryonic and adult stem-cell proliferation, survival, differentiation, and stemness relevant to tissue regeneration and aging — conceptual synthesis of heterogeneous preclinical reports, no new primary data and no clinical translation. [mechanism-plausible] (novelty: 3)
- 2026-09-28 — Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.: Perspective review reframes incretin-associated lean-mass loss as physiological body-composition remodeling comparable to other weight-loss modalities, accompanied by preferential fat loss and preserved/improved physical function rather than pathological sarcopenia — synthesis argument, no new primary data. [expert-opinion] (novelty: 3)
- 2025-10-24 — Impact of GLP-1 receptor agonists on cardiovascular outcomes in patients with peripheral artery disease without diabetes: A propensity score-matched analysis.: Propensity-matched real-world cohort in nondiabetic peripheral artery disease patients found GLP-1 RA use associated with substantially lower MACE, all-cause mortality, and major adverse limb events — observational extension of cardiovascular/limb benefit into a non-diabetic PAD population, no RCT confirmation. [human-observational] (novelty: 3)
- 2026-10-01 — Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.: Prespecified indirect imputed-placebo analysis of SURPASS-CVOT using REWIND as the placebo anchor estimated tirzepatide reduced MACE-3 (HR ~0.72), CV death or heart-failure events, and all-cause death vs placebo in T2D with established ASCVD — indirect/imputed comparison extending GLP-1RA CVOT evidence to a dual GIP/GLP-1 agonist, not a head-to-head placebo RCT. [human-rct] (novelty: 3)
- 2026-05-15 — Divergent Risks of Endocrine and Nonendocrine Malignancies in GLP-1 Receptor Agonist Users: A Propensity-Matched Real-World Analysis of Over 140 000 Patients.: Propensity-matched real-world cohort (~144k T2D adults on GLP-1 RAs) reported lower all-cause mortality and reduced nonendocrine cancer incidence versus matched controls, while an early thyroid cancer signal attenuated by year 3 and was interpreted as surveillance bias — observational site-specific oncology data, not an RCT. [human-observational] (novelty: 3)
- 2026-09-26 — GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.: Systematic review/meta-analysis of 14 trials (n=15,882 HF patients) found GLP-1 RAs reduced MACE, HF hospitalization, CV death/worsening-HF events, and all-cause mortality in HFpEF—especially overweight/obese patients and with semaglutide—while HFrEF benefit remained limited; phenotype-stratified synthesis of existing RCTs, no new primary trial. [human-rct] (novelty: 3)
- 2026-09-27 — Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.: Large propensity-matched real-world CKD cohort found adding a GLP-1 RA to SGLT2i therapy associated with substantially lower major adverse kidney events, MACE, and all-cause mortality versus SGLT2i alone — observational additive-benefit signal, no RCT confirmation of the combination. [human-observational] (novelty: 3)
- 2026-09-19 — Can semaglutide slow aging?: Attia expert-media commentary on a new mouse study reporting semaglutide extended median lifespan and improved aging measures in female mice, flagging the headline as requiring careful interpretation — expert framing of a preclinical signal, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-17 — Muscle Percentage Is Not Muscle Preservation: Interpreting Body-Composition Outcomes During GLP-1 Weight Loss.: Interpretive review argues that improvements in muscle-as-percent-of-body-mass during GLP-1 weight loss do not equate to muscle preservation, and that body-composition claims should be judged on absolute lean mass and functional endpoints — methodological correction, no new trial data. [expert-opinion] (novelty: 3)
- 2026-09-19 — Changes in Body Composition Assessed by Bioelectrical Impedance Analysis in Patients Treated with GLP-1 Receptor Agonists: A Real-World Experience.: Real-world BIA cohort (n=388) on GLP-1 RAs found ~11.3% weight loss at 6 months driven predominantly by fat and visceral fat reduction with only modest skeletal muscle loss — observational body-composition data consistent with the muscle-loss signal but suggesting fat-preferential loss in routine practice. [human-observational] (novelty: 3)
- 2026-09-20 — Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP.: Prespecified MRI secondary analysis of the phase 3b STEP UP RCT found semaglutide reduced adipose tissue and thigh intramuscular fat infiltration with modest skeletal muscle volume loss and preserved sit-to-stand physical function in adults with obesity — direct human RCT body-composition/function data refining the muscle-loss debate. [human-rct] (novelty: 3)
- 2026-09-21 — Can Obesity Pharmacotherapy Modify Osteoarthritis? Interpreting Pain Relief, Weight-Loss Quality, and Structural Outcomes.: Narrative review on obesity pharmacotherapy in osteoarthritis concludes GLP-1 RAs and multi-agonists deliver substantial OA pain relief in class-III obesity RCTs via weight loss but show no structural joint modification and carry muscle/bone loss risk, so should not be labeled disease-modifying OA therapy. [expert-opinion] (novelty: 3)
- 2026-09-25 — An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.: Preclinical combination study: adipose-directed ZFP423 ASO plus semaglutide in mice produced greater fat loss than either agent alone while preserving lean mass — proposes a beiging-based adjunct to address GLP-1’s lean-mass liability, no human data. [animal-model] (novelty: 4)
- 2026-09-25 — The Interplay of Metabolic Dysfunction, Neuroinflammation, and Mitochondrial Dysfunction in Balance Impairment: Insights from Type 2 Diabetes Mellitus and Alzheimer’s Disease.: Narrative review of T2DM/Alzheimer’s balance impairment frames GLP-1 agonists as candidate interventions targeting a shared insulin resistance–NLRP3 neuroinflammation–mitochondrial dysfunction cycle affecting motor circuits, muscle, and nerve — mechanistic synthesis, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-09-26 — Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.: Observational comparative study in elderly patients with HFpEF and obesity found oral semaglutide associated with lower incident cognitive impairment vs DPP-4 inhibitors — active-comparator cohort, extending the neurocognitive signal into a narrow HFpEF+obesity subgroup without RCT confirmation. [human-observational] (novelty: 3)
- 2026-09-21 — GLP-1 Analogues and Long-term Outcomes in Adults with Obesity and Elevated CRP: A Real-world Matched Cohort Study.: Propensity-matched real-world cohort (~50k per arm) in adults with obesity and CRP 3–10 mg/L found GLP-1 RA exposure associated with lower long-term all-cause mortality and composite CV events versus other anti-obesity medications, extending the cardioprotective signal into an inflammation-selected, longer-horizon population. [human-observational] (novelty: 3)
- 2026-09-22 — Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial.: Transportability analysis re-weighting LEADER trial effects onto a VA veteran cohort with diabetes projected larger 3-year absolute reductions in MACE and all-cause mortality with liraglutide than in the original RCT, suggesting the trial’s cardioprotective signal may under-represent benefit in higher-risk real-world populations. [human-observational] (novelty: 3)
- 2026-05-26 — GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.: Propensity-matched retrospective multicenter cohort in adults with Lp(a) >50 mg/dL plus obesity or T2D found GLP-1 RA use associated with substantially lower all-cause mortality and MACE, extending cardioprotective signal into a high-risk subgroup with few targeted options. [human-observational] (novelty: 3)
- 2026-09-14 — GLP-1 receptor agonists, epigenetic aging, and the prospect of pharmacological healthspan extension.: Narrative review integrates SELECT-class mortality and kidney RCT outcomes with a 2025 randomized signal that semaglutide decelerates validated DNA-methylation aging clocks, positioning GLP-1 RAs as candidate gerotherapeutics pending trials with prespecified aging endpoints. [expert-opinion] (novelty: 3)
- 2026-09-16 — Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.: Post-hoc analysis of the SELECT RCT (semaglutide 2.4 mg weekly) stratified by Rockwood frailty index found consistent reductions in major CV and clinical events across frailty strata, with frailty category and health-related quality of life improving more often in participants with higher baseline frailty. [human-rct] (novelty: 3)
- 2026-09-12 — GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.: Systematic review and meta-analysis of GLP-1 RAs across musculoskeletal outcomes found consistent lean/fat-free mass reductions largely proportional to weight loss (low certainty), with no significant effects on bone mineral density, fractures, or WOMAC joint scores — first broad synthesis quantifying the muscle-loss signal while ruling out (at current evidence) bone/joint harm. [human-rct] (novelty: 3)
- 2026-08-12 — Comparing Facial Aging Between Identical Twins With 3D Imaging: Planned 2026 identical-twin study will use non-contact 3D facial imaging plus lifestyle questionnaires to isolate environmental drivers of facial aging within genetically matched pairs, with a dedicated GLP-1 agonist (‘Ozempic face’) arm — study design announcement, no results yet. [human-observational] (novelty: 3)
- 2026-07-20 — Mapping the Impact of Glucagon-Like Peptide-1 Receptor Agonists on Aesthetic and Reconstructive Plastic Surgery: A Bibliometric Analysis of the 50 Most Cited Studies.: Bibliometric analysis of the 50 most-cited GLP-1 RA papers in aesthetic/plastic surgery finds the literature is almost entirely 2023–2025 and clusters around facial aesthetic aging (‘Ozempic face’), perioperative safety, and post-weight-loss body contouring, but remains descriptive and conceptually immature — trend-mapping review, no new primary outcome data. [expert-opinion] (novelty: 3)
- 2026-07-21 — Lifestyle Intervention to Reduce the Risk of Sarcopenia in Adults With Diabetes & Obesity Treated With Semaglutide: Protocol/aims description of an early RCT testing a multi-disciplinary exercise-plus-nutrition intervention vs. standard advice to blunt sarcopenia (muscle mass, strength, physical function) in adults 65+ with T2D and obesity on weekly semaglutide — trial design only, no efficacy readout. [human-rct] (novelty: 3)
- 2026-08-28 — HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide: New double-blind RCT in adults 65–85 with T2D newly initiating semaglutide will test whether calcium-HMB plus vitamin D3 preserves appendicular lean mass, physical function, and resting metabolism over ~6 months — first RCT of a nutraceutical adjunct specifically targeting GLP-1-associated muscle loss in older adults. [human-rct] (novelty: 4)
- 2026-07-20 — Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women: Planned/early-stage trial to test semaglutide and tirzepatide weight loss for effects on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity — geroscience-endpoint trial announced, no results yet. [human-rct] (novelty: 3)
- 2026-09-08 — Why GLP-1s Could Be an Anti-Aging Breakthrough: National Geographic mainstream feature frames GLP-1 receptor agonists as a potential anti-aging breakthrough beyond metabolic indications — general-audience science media coverage, no new primary data. [expert-opinion] (novelty: 4)
- 2026-06-29 — #398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss: Attia AMA (expert-media) argues that with adequate protein intake and structured resistance training, GLP-1 RA-associated lean-mass loss during weight loss is minimal — clinical framing, no new primary data. [expert-opinion] (novelty: 3)
- 2026-08-27 — GLP-1 medications beyond weight loss: how far could their benefits extend?: Attia expert-media synthesis surveys the expanding list of established and emerging non-weight-loss indications for GLP-1 agonists (cardiovascular, renal, neurocognitive, addiction, inflammatory) — credentialed roundup, no new primary data. [expert-opinion] (novelty: 3)
- 2026-09-08 — Late-Life GLP-1 Treatment Increases Lifespan in Female Mice: News report on late-life semaglutide in female mice: >12% median lifespan extension plus healthspan marker improvements — mouse study, not yet peer-reviewed primary data seen here. [animal-model] (novelty: 4)
- 2026-09-04 — Akkermansia muciniphila and Its Bioactive Derivatives: Emerging Regulators of Healthy Aging: cross-connection with akkermansia-muciniphila: Review notes A. muciniphila’s metabolic effects overlap with GLP-1-related pathways (incretin modulation, insulin sensitivity), linking microbiome and pharmacologic metabolic-aging interventions. (novelty: 3)
- 2026-03-25 — Senolytic therapy ameliorates high-fat diet-induced hippocampal senescence and cognitive decline in mice.: cross-connection with senolytics: Both are candidate interventions on obesity-driven neurocognitive decline — senolytics by clearing HFD-induced hippocampal senescent cells, GLP-1RAs by reducing the upstream metabolic drive; complementary rather than redundant. (novelty: 3)
- 2026-08-05 — The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.: Narrative review positions GLP-1 agonists as a mid-tier rung on a tiered prevention ladder (lifestyle/statins → GLP-1 → senolytics) targeting adipose-derived metainflammation as an immunometabolic bridge from preclinical obesity to CVD; conceptual synthesis, no new primary data. [expert-opinion] (novelty: 3)
- 2026-07-14 — Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.: Real-world observational cohort of older adults (including ≥75) with T2D on tirzepatide over 6 months found significant HbA1c and BMI reductions with no severe hypoglycemia when insulin/sulfonylureas/glinides were preemptively down-titrated, though excessive weight loss was flagged as a monitoring concern. [human-observational] (novelty: 3)
- 2026-07-16 — Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist-Mediated Cardioprotection.: Narrative review reframes GLP-1RA cardioprotection as prevention of vascular aging — improved endothelial/vascular progenitor cell flux and dampened senescence-associated secretory inflammation — synthesizing prior mechanistic and progenitor-cell work rather than adding new outcome data. [expert-opinion] (novelty: 3)
- 2026-07-16 — Glucagon-like peptide-1 receptor agonists in the aging population of people with HIV: emerging evidence and clinical implications.: Purpose-of-review synthesis on GLP-1 RAs in aging people with HIV reports meaningful reductions in weight, glycemia, and visceral/hepatic fat with generally reassuring functional data, but notes evidence specifically in older PWH remains sparse — narrative review, no new primary trial. [expert-opinion] (novelty: 3)
- 2026-08-01 — A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health.: In silico QSP model (calibrated to STEP trial and meta-analytic drug effects) predicts GLP-1 RA appears in BOTH the metabolic-optimal (GLP-1+SGLT2+metformin) and aging-optimal (GLP-1+SGLT2+rapamycin) triple combinations, but the two optima diverge — hypothesis-generating simulation, no new human outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-03 — Anti-Obesity Medications in Longevity and Aesthetic Medicine.: Narrative review integrating CV/renal outcome RCTs, exploratory proteomic and epigenetic biomarker signals, multi-receptor agonist body-composition data, and aesthetic soft-tissue/lean-mass effects into a longevity-medicine frame; hard outcomes (MACE, renal/hepatic progression, all-cause mortality) rest on RCTs in selected populations, while weight-independent aging biomarker and aesthetic claims remain hypothesis-level. [expert-opinion] (novelty: 3)
- 2026-08-01 — Lactiplantibacillus plantarum AS21 Attenuates Sex-Biased Glucose Intolerance in Aging Mice via Gut Mucosal Microbiota-Derived Citrulline.: cross-connection with citrulline: Citrulline enhances endogenous GLP-1 secretion in aged mice, linking an amino acid intermediate to the same incretin axis targeted pharmacologically by GLP-1 agonists. (novelty: 3)
- 2026-08-01 — The GLP-1-Mitochondria Axis in Metabolic Aging.: Narrative review proposes a GLP-1–mitochondria axis (biogenesis, dynamics, mitophagy) linking SELECT outcomes to a 2025 mouse multi-omic study; no human trial has used a prespecified mitochondrial endpoint, so the aging-relevant mechanism remains hypothesis-level. [mechanism-plausible] (novelty: 3)
- 2026-08-05 — Citrus Changshan Huyou extracts as natural GLP-1R agonists attenuate atherosclerosis via the GLP-1R/PKA/CREB pathway: a functional food perspective.: ApoE-knockout mouse study reports Citrus Changshan Huyou extract and five constituent flavonoids act as natural GLP-1R agonists, reducing atherosclerotic plaque, vascular senescence, and aortic inflammation via intestinal GLP-1R/PKA/CREB signaling — preclinical food-derived agonism, no human data. [animal-model] (novelty: 3)
- 2026-08-13 — Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.: Mouse study (UUO + aged mice) comparing semaglutide, tirzepatide, and retatrutide found all three reduced renal fibrosis via distinct pathway signatures, with the triple agonist retatrutide showing the largest antifibrotic effect at tested doses — preclinical only, no human kidney-outcome data. [animal-model] (novelty: 3)
- 2026-08-21 — Immunometabolic reprogramming via GLP-1 receptor agonists in people with HIV: A multidimensional systemic framework.: Review synthesizing RCT, cohort, and mechanistic data on GLP-1 RAs in people with HIV reports reductions in visceral adiposity, weight, inflammatory biomarkers, and hepatic steatosis; framed immunologic and gerotherapeutic extensions as hypothesis-generating rather than established. [expert-opinion] (novelty: 3)
- 2026-08-14 — Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity.: Narrative review (RCTs + observational) reports semaglutide and tirzepatide reduce lean body mass roughly in proportion to total weight loss, with tirzepatide showing possible improvement in muscle fat infiltration; authors argue protein intake, resistance exercise, and functional assessment should be integrated into incretin-based obesity care, especially in older adults. [expert-opinion] (novelty: 3)
Open questions
Related
Contributing findings
Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.
13-nov-2026
novelty 3
per-area 3
strengthens
Could microdosing GLP-1 drugs boost longevity?
12-nov-2026
novelty 3
per-area 3
strengthens
Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?
12-nov-2026
novelty 3
per-area 3
strengthens
Why We May Soon Add ‘Anti-Aging’ to GLP-1s’ Growing Benefits
11-nov-2026
novelty 2
per-area 2
mentions
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026
novelty 4
per-area 4
strengthens
Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
10-nov-2026
novelty 3
per-area 3
strengthens
GLP-1-Based Therapies Across the Menopausal Transition: Dermatologic Considerations and Practical Management.
10-nov-2026
novelty 2
per-area 2
mentions
Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes
09-nov-2026
novelty 3
per-area 3
strengthens
Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP-1 Weight Loss.
08-nov-2026
novelty 3
per-area 3
strengthens
Obesity pharmacotherapies and cognition.
05-nov-2026
novelty 3
per-area 3
strengthens
GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
04-nov-2026
novelty 3
per-area 3
strengthens
Tirzepatide for the treatment of obstructive sleep apnea: from apnea-hypopnea index reduction to cardiometabolic risk mitigation-a narrative review.
04-nov-2026
novelty 2
per-area 2
strengthens
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
01-nov-2026
novelty 3
per-area 3
strengthens
Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
30-oct-2026
novelty 3
per-area 3
strengthens
Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.
30-oct-2026
novelty 3
per-area 3
strengthens
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
29-oct-2026
novelty 3
per-area 3
strengthens
GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.
29-oct-2026
novelty 3
per-area 3
strengthens
Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.
28-oct-2026
novelty 3
per-area 3
strengthens
The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.
27-oct-2026
novelty 2
per-area 2
strengthens
Cardiovascular Effects of GLP-1 Receptor Agonists Across Age Groups: An Updated Meta-Analysis of Randomized Controlled Trials.
27-oct-2026
novelty 3
per-area 3
strengthens
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.
26-oct-2026
novelty 3
per-area 3
strengthens
Effect of glucagon-like-peptide-1 receptor agonists on major cardiovascular outcomes: a systematic review and meta-analysis.
26-oct-2026
novelty 2
per-area 2
strengthens
Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.
22-oct-2026
novelty 3
per-area 3
strengthens
Correction: Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trialanalysis.
19-oct-2026
novelty 1
per-area 1
mentions
GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.
18-oct-2026
novelty 2
per-area 2
strengthens
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026
novelty 3
per-area 3
strengthens
GLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational study.
16-oct-2026
novelty 3
per-area 3
strengthens
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.
15-oct-2026
novelty 2
per-area 2
strengthens
"Ozempic Face" and Facial Aging.
10-oct-2026
novelty 3
per-area 3
strengthens
Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
09-oct-2026
novelty 3
per-area 3
strengthens
Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy.
07-oct-2026
novelty 3
per-area 3
strengthens
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
05-oct-2026
novelty 2
per-area 2
mentions
Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.
05-oct-2026
novelty 3
per-area 3
strengthens
Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.
02-oct-2026
novelty 3
per-area 3
strengthens
Semaglutide Demonstrates Benefits Across Frailty Levels.
02-oct-2026
novelty 3
per-area 3
strengthens
Are we at risk of increasing sarcopenia? Implications for osteoarthritis and osteoporosis.
02-oct-2026
novelty 2
per-area 3
weakens
Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.
01-oct-2026
novelty 3
per-area 3
strengthens
Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.
01-oct-2026
novelty 3
per-area 3
strengthens
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
01-oct-2026
novelty 3
per-area 3
strengthens
Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.
30-sep-2026
novelty 2
per-area 2
strengthens
Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.
29-sep-2026
novelty 3
per-area 3
strengthens
Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.
29-sep-2026
novelty 2
per-area 2
strengthens
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
28-sep-2026
novelty 2
per-area 2
strengthens
Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity.
28-sep-2026
novelty 2
per-area 2
strengthens
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.
28-sep-2026
novelty 3
per-area 3
strengthens
Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.
27-sep-2026
novelty 3
per-area 3
strengthens
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
27-sep-2026
novelty 3
per-area 3
strengthens
GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
26-sep-2026
novelty 3
per-area 3
strengthens
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
26-sep-2026
novelty 3
per-area 3
strengthens
An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.
25-sep-2026
novelty 4
per-area 4
strengthens